The important molecular markers on chromosome 17 and their clinical impact in breast cancer
- PMID: 22016618
- PMCID: PMC3189742
- DOI: 10.3390/ijms12095672
The important molecular markers on chromosome 17 and their clinical impact in breast cancer
Abstract
Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppressor genes (p53, BRCA1 and HIC-1) or DNA double-strand break repair gene (RDM1) are located on chromosome 17. We searched the literature on HER2, TOP2A, TAU, RDM1, p53, BRCA1 and HIC-1 on the Pubmed database. The association of genes with chromosome 17, biological functions and potential significance are reviewed. In breast cancer, the polysomy 17 (three or more) is the predominant numerical aberration. HER2 amplification is widely utilized as molecular markers for trastuzumab target treatment. Amplified TOP2A, TAU and RDM1 genes are related to a significant response to anthracycline-based chemotherapy, taxane or cisplatin, respectively. In contrast, p53, BRCA1 and HIC-1 are important tumor suppressor genes related to breast carcinogenesis. This review focused on several crucial molecular markers residing on chromosome 17. The authors consider the somatic aberrations of chromosome 17 and associated genes in breast cancer.
Keywords: biomarkers; breast cancer; chromosome 17.
Figures
Similar articles
-
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26. J Clin Oncol. 2011. PMID: 21947821
-
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163. BMC Cancer. 2013. PMID: 23537287 Free PMC article.
-
[Clinicopathologic significance of chromosome 17 polysomy in breast cancer].Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):88-91. Zhonghua Bing Li Xue Za Zhi. 2008. PMID: 18681318 Chinese.
-
[In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer].Pathologe. 2012 Nov;33 Suppl 2:307-10. doi: 10.1007/s00292-012-1663-z. Pathologe. 2012. PMID: 23052344 Review. German.
-
Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.Oncogene. 2010 Sep 23;29(38):5231-40. doi: 10.1038/onc.2010.286. Epub 2010 Aug 2. Oncogene. 2010. PMID: 20676126 Review.
Cited by
-
Evaluation of HER2 gene amplification in breast cancer using nuclei microarray in situ hybridization.Int J Mol Sci. 2012;13(5):5519-5527. doi: 10.3390/ijms13055519. Epub 2012 May 8. Int J Mol Sci. 2012. PMID: 22754312 Free PMC article.
-
ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression.Cancer Cell Int. 2022 May 2;22(1):179. doi: 10.1186/s12935-022-02596-w. Cancer Cell Int. 2022. PMID: 35501800 Free PMC article.
-
FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.Histopathology. 2014 Sep;65(3):371-88. doi: 10.1111/his.12396. Histopathology. 2014. PMID: 25353038 Free PMC article.
-
An RNA-seq-based gene expression profiling of radiation-induced tumorigenic mammary epithelial cells.Genomics Proteomics Bioinformatics. 2012 Dec;10(6):326-35. doi: 10.1016/j.gpb.2012.11.001. Epub 2012 Dec 4. Genomics Proteomics Bioinformatics. 2012. PMID: 23317700 Free PMC article.
-
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2395-2401. doi: 10.31557/APJCP.2020.21.8.2395. Asian Pac J Cancer Prev. 2020. PMID: 32856871 Free PMC article.
References
-
- Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19:554–568. - PubMed
-
- Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Modern Pathol. 1998;11:870–877. - PubMed
-
- Sharif S, Ramanathan RK, Potter D, Cieply K, Krasinskas AM. HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. Digest Dis Sci. 2008;53:3026–3032. - PubMed
-
- Shafizadeh N, Grenert JP, Sahai V, Kakar S. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol. 2010;41:485–492. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous